140 related articles for article (PubMed ID: 19695569)
1. Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance.
Wada H; Satoh N; Kitaoka S; Ono K; Morimoto T; Kawamura T; Nakano T; Fujita M; Kita T; Shimatsu A; Hasegawa K
Atherosclerosis; 2010 Feb; 208(2):512-7. PubMed ID: 19695569
[TBL] [Abstract][Full Text] [Related]
2. Disruption of components of vascular endothelial growth factor angiogenic signalling system in metabolic syndrome. Findings from a study conducted in rural Bangladeshi women.
Jesmin S; Akter S; Rahman MM; Islam MM; Islam AM; Sultana SN; Mowa CN; Yamaguchi N; Okazaki O; Satoru K; Kimura S; Hiroe M; Mizutani T; Moroi M
Thromb Haemost; 2013 Apr; 109(4):696-705. PubMed ID: 23364276
[TBL] [Abstract][Full Text] [Related]
3. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.
Wierzbowska A; Robak T; Wrzesień-Kuś A; Krawczyńska A; Lech-Marańda E; Urbańska-Ryś H
Eur Cytokine Netw; 2003; 14(3):149-53. PubMed ID: 14656688
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
[TBL] [Abstract][Full Text] [Related]
5. Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer.
Thielemann A; Baszczuk A; Kopczyński Z; Kopczyński P; Grodecka-Gazdecka S
Ann Agric Environ Med; 2013; 20(2):293-7. PubMed ID: 23772579
[TBL] [Abstract][Full Text] [Related]
6. Selected angiogenic factors in plasma of patients with lower limb symptomatic peripheral arterial disease: preliminary report.
Wieczór R; Gadomska G; Góralczyk B; Stankowska K; Budzyński J; Fabisiak J; Suppan K; Pulkowski G; Rość D
Int Angiol; 2015 Dec; 34(6):545-51. PubMed ID: 25394959
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of soluble vascular endothelial growth factor receptor-1 prevents angiogenesis in hypertrophied myocardium.
Kaza E; Ablasser K; Poutias D; Griffiths ER; Saad FA; Hofstaetter JG; del Nido PJ; Friehs I
Cardiovasc Res; 2011 Feb; 89(2):410-8. PubMed ID: 20935166
[TBL] [Abstract][Full Text] [Related]
8. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma.
Ebos JM; Bocci G; Man S; Thorpe PE; Hicklin DJ; Zhou D; Jia X; Kerbel RS
Mol Cancer Res; 2004 Jun; 2(6):315-26. PubMed ID: 15235107
[TBL] [Abstract][Full Text] [Related]
9. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy.
Matsunaga N; Chikaraishi Y; Izuta H; Ogata N; Shimazawa M; Matsumura M; Hara H
Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666
[TBL] [Abstract][Full Text] [Related]
10. VEGF and its soluble receptor VEGFR-2 in hypertensive disorders during pregnancy: the Indian scenario.
Rath G; Tripathi R
J Hum Hypertens; 2012 Mar; 26(3):196-204. PubMed ID: 21412269
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus.
Robak E; Sysa-Jedrzejewska A; Robak T
Mediators Inflamm; 2003 Oct; 12(5):293-8. PubMed ID: 14760936
[TBL] [Abstract][Full Text] [Related]
12. Impact of type 2 diabetes on the plasma levels of vascular endothelial growth factor and its soluble receptors type 1 and type 2 in patients with peripheral arterial disease.
Wieczór R; Gadomska G; Ruszkowska-Ciastek B; Stankowska K; Budzyński J; Fabisiak J; Suppan K; Pulkowski G; Rość D
J Zhejiang Univ Sci B; 2015 Nov; 16(11):948-56. PubMed ID: 26537213
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor and its soluble receptors-1 and -2 in iris neovascularization and neovascular glaucoma.
Noma H; Mimura T; Yasuda K; Shimura M
Ophthalmologica; 2014; 232(2):102-9. PubMed ID: 24942011
[TBL] [Abstract][Full Text] [Related]
14. The usefulness of determining the serum concentrations of vascular endothelial growth factor (VEGF) and its soluble receptor type 2 (sVEGF-2) in the differential diagnosis of adrenal incidentalomas.
Foltyn W; Strzelczyk J; Marek B; Kajdaniuk D; Siemińska L; Rosiek V; Kos-Kudła B
Endokrynol Pol; 2012; 63(1):22-8. PubMed ID: 22378094
[TBL] [Abstract][Full Text] [Related]
15. Circulating vascular endothelial growth factor (VEGF) and its soluble receptor 1 (sVEGFR-1) are associated with inflammation and mortality in incident dialysis patients.
Yuan J; Guo Q; Qureshi AR; Anderstam B; Eriksson M; Heimbürger O; Bárány P; Stenvinkel P; Lindholm B
Nephrol Dial Transplant; 2013 Sep; 28(9):2356-63. PubMed ID: 23828162
[TBL] [Abstract][Full Text] [Related]
16. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC.
Jantus-Lewintre E; Sanmartín E; Sirera R; Blasco A; Sanchez JJ; Tarón M; Rosell R; Camps C
Lung Cancer; 2011 Nov; 74(2):326-31. PubMed ID: 21481963
[TBL] [Abstract][Full Text] [Related]
17. Overweight and obesity versus concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 in plasma of patients with lower limb chronic ischemia.
Wieczór R; Wieczór AM; Gadomska G; Stankowska K; Fabisiak J; Suppan K; Pulkowski G; Budzyński J; Rość D
J Zhejiang Univ Sci B; 2016 Nov.; 17(11):842-849. PubMed ID: 27819131
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic effect of soluble vascular endothelial growth factor receptor-1 in placental angiogenesis.
Ahmad S; Ahmed A
Endothelium; 2005; 12(1-2):89-95. PubMed ID: 16036320
[TBL] [Abstract][Full Text] [Related]
19. Insulin resistance and the metabolic syndrome are associated with arterial stiffness in patients with chronic kidney disease.
Chan DT; Watts GF; Irish AB; Ooi EM; Dogra GK
Am J Hypertens; 2013 Sep; 26(9):1155-61. PubMed ID: 23736110
[TBL] [Abstract][Full Text] [Related]
20. Reduced serum vascular endothelial growth factor receptor-2 (sVEGFR-2) and sVEGFR-1 levels in gastric cancer patients.
Kikuchi S; Obata Y; Yagyu K; Lin Y; Nakajima T; Kobayashi O; Kikuichi M; Ushijima R; Kurosawa M; Ueda J
Cancer Sci; 2011 Apr; 102(4):866-9. PubMed ID: 21219538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
